{"id":"taurolidine-urokinase","safety":{"commonSideEffects":[{"rate":"null","effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL2105420","moleculeType":"Small molecule","molecularWeight":"284.36"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Taurolidine has antimicrobial properties that help to reduce bacterial load, while urokinase has fibrinolytic properties that help to break down blood clots and promote wound healing. This combination makes taurolidine urokinase effective in treating infections and promoting wound healing.","oneSentence":"Taurolidine urokinase works by combining the antimicrobial properties of taurolidine with the fibrinolytic properties of urokinase to treat infections and promote wound healing.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:31.664Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of catheter-related bloodstream infections"}]},"trialDetails":[{"nctId":"NCT02036255","phase":"PHASE3","title":"Prevention of Dialysis Catheter Malfunction With Prophylactic Use of a Taurolidine Containing Urokinase","status":"COMPLETED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2015-05","conditions":"Patency, Infection","enrollment":68},{"nctId":"NCT02789501","phase":"PHASE4","title":"Comparison of a TauroLock™ Based Regimen to 4% Citrate as Lock Solution in Tunneled Haemodialysis Catheters for the Prevention of Bacteraemia and Dysfunction","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2012-01","conditions":"Catheter Infections, End-stage Renal Disease","enrollment":106},{"nctId":"NCT02868697","phase":"PHASE4","title":"Management of Tunneled Catheter Thrombosis in Hemodialysis Patients: Prospective Study From Qatar","status":"COMPLETED","sponsor":"Hamad Medical Corporation","startDate":"2013-11","conditions":"Hemodialysis, Tunneled Catheter, Qatar","enrollment":170}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Taurolock Urokinase 25,000"],"phase":"phase_3","status":"active","brandName":"Taurolidine Urokinase","genericName":"Taurolidine Urokinase","companyName":"Universitair Ziekenhuis Brussel","companyId":"universitair-ziekenhuis-brussel","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Taurolidine urokinase works by combining the antimicrobial properties of taurolidine with the fibrinolytic properties of urokinase to treat infections and promote wound healing. Used for Treatment of catheter-related bloodstream infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}